Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open, Multicenter Clinical Observational Study of Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

NCT05486013 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05486013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open, Multicenter Clinical Observational Study of Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 26, 2022
Completion date
November 26, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma